"Benzimidazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a BENZENE fused to IMIDAZOLES.
| Descriptor ID |
D001562
|
| MeSH Number(s) |
D03.633.100.103
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzimidazoles".
Below are MeSH descriptors whose meaning is more specific than "Benzimidazoles".
This graph shows the total number of publications written about "Benzimidazoles" by people in this website by year, and whether "Benzimidazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 2 | 2 |
| 2001 | 2 | 2 | 4 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 3 | 3 | 6 |
| 2006 | 3 | 0 | 3 |
| 2007 | 0 | 1 | 1 |
| 2008 | 4 | 0 | 4 |
| 2009 | 3 | 1 | 4 |
| 2010 | 2 | 1 | 3 |
| 2011 | 6 | 0 | 6 |
| 2012 | 12 | 4 | 16 |
| 2013 | 4 | 2 | 6 |
| 2014 | 7 | 1 | 8 |
| 2015 | 3 | 2 | 5 |
| 2016 | 5 | 3 | 8 |
| 2017 | 4 | 3 | 7 |
| 2018 | 3 | 4 | 7 |
| 2019 | 4 | 1 | 5 |
| 2020 | 0 | 2 | 2 |
| 2021 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzimidazoles" by people in Profiles.
-
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. J Clin Oncol. 2021 11 10; 39(32):3633-3644.
-
Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2021 09; 159:56-65.
-
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. Gynecol Oncol. 2021 08; 162(2):375-381.
-
A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101. Oral Oncol. 2021 03; 114:105171.
-
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial. JCO Precis Oncol. 2021; 5.
-
Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib. Br J Cancer. 2021 01; 124(1):176-182.
-
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. J Clin Oncol. 2020 05 01; 38(13):1378-1388.
-
Reinvestigating the synthesis and efficacy of small benzimidazole derivatives as presequence protease enhancers. Eur J Med Chem. 2019 Dec 15; 184:111746.
-
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019 12 19; 381(25):2403-2415.
-
Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers. PLoS One. 2019; 14(9):e0221957.